H.R. 4764 (106th): To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs.

Introduced:
Jun 27, 2000 (106th Congress, 1999–2000)
Sponsor:
Rep. Thomas Ewing [R-IL15]
Status:
Died (Referred to Committee)

The bill’s title was written by the bill’s sponsor. H.R. stands for House of Representatives bill.

(About Ads | Advertise Here)
Status

This bill was introduced on June 27, 2000, in a previous session of Congress, but was not enacted.

Progress
Introduced Jun 27, 2000
Cosponsors
2 cosponsors (2R) (show)
Committees

House Ways and Means

The committee chair determines whether a bill will move past the committee stage.

Summary

No summaries available.

Text

Read Bill Text »

Last updated Jun 27, 2000.
5 pages

Primary Source

View on THOMAS (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here.

Citation

Click a format for a citation suggestion:

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

6/27/2000--Introduced.
Directs the United States Trade Representative (USTR) to enter into negotiations with the Governments of the other G-8 countries (Canada, France, Germany, Great Britain, Italy, Japan, Russia, and the United States) in order to achieve their agreement to eliminate price controls on innovative medicines and the unfair trade practices that result from the application of price controls.
Declares that, if within 12 months negotiations have not achieved such objectives, the USTR shall recommend to Congress the most effective measures (including those specified by the Trade Act of 1974) for eliminating the disparity between the price of prescription drugs in the United States and the price of prescription drugs in the other G-8 countries, with the goal of reducing the price of prescription drugs for U.S. consumers.
Requires recommended measures to be of a nature and amount that fully reflect the economic harm inflicted on patients and health care in the United States, and the harm inflicted on the U.S. economy when countries pay the country specific marginal costs of prescription drugs and let the United States cover the research and development costs of innovative prescription drugs.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

The bill contains the following citations to other parts of U.S. law:

United States Code

The United States Code is the compilation of permanent laws enacted by Congress. Temporary and other non-permanent laws do not appear in the United States Code. (About half of the United States Code is the law itself, called positive law. The other half is merely a compilation of the laws but has no legal significance.)